Can personality disorder treatments be reduced to just a few months?

In this episode, co-hosted by our Senior Editor Amy Slogrove and our Lancet Child & Adolescent Health Youth Advisory Panel member, Matea Canizares, we discuss adolescent digital intimate partner violence.

Join Senior Editor Stephanie Becker in an insightful conversation with Santiago Madero as they explore the evolving perspectives on psychedelic treatments, the latest developments in regulatory frameworks, and advances in psychedelic research.

The uniqueness of each patient is at the heart of this year's World Cancer Day. In this Podcast you will hear from two cancer survivors about their unique experience with cancer and the importance of personalised cancer care not only on their bodies but also on their lives.

In Conversation with The Lancet returns with Dr Susannah Stanway, honorary consultant medical oncologist at the Royal Marsden and honorary clinical senior lecturer in Education at the Institute of Cancer Research, reflecting on London Global Cancer Week 2025.

Franck Morschhauser joins Ben Abbott of The Lancet to discuss the phase 3 EPCORE FL-1 study on epcoritamab, lenalidomide, and rituximab for relapsed or refractory follicular lymphoma, which is being presented at ASH 2025.

Professor Arnon Kater and Dr Sabina Kersting join us to discuss the results of their phase 2 trial testing a new first-line treatment regimen in chronic lymphocytic leukaemia: fixed-duration ibrutinib–venetoclax followed by MRD-guided ibrutinib–obinutuzumab intensification.

Ultra-processed foods are on the rise. Despite the emphasis placed on individual responsibility, our deteriorating diets are primarily the result of the sophisticated political tactics of a powerful global ultra-processed food industry.

Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025.

Neal Shore joins Ben Abbott of The Lancet to discuss the phase 3 POTOMAC trial of durvalumab plus BCG in BCG-naïve, high-risk non-muscle-invasive bladder cancer, which is being presented at ESMO 2025.